20. November 2009 03:27
For the first time, scientists have successfully used a method called exome sequencing to quickly discover a previously unknown gene responsible for a mendelian disorder.
[More]
17. November 2009 01:29
Scientists at the University of Pennsylvania School of Medicine discovered that a dietary antioxidant found in such vegetables as broccoli and cauliflower protects cells from damage caused by chemicals generated during the body's inflammatory response to infection and injury. The finding has implications for such inflammation-based disorders as cystic fibrosis (CF), diabetes, heart disease, and neurodegeneration.
[More]
e5c6cb22-b74f-4132-a572-92c65a5fab7d|0|.0
Posted in: Medical Science News | Disease/Infection News
Tags: Antioxidant, Atherosclerosis, Biochemistry, Blood Vessel, Cardiovascular Disease, Cell, Cystic Fibrosis, Diabetes, Digestive System, Education, Fibrosis, Hospital, Hydrogen Peroxide, Neurodegeneration, Obstetrics, Pathology, Physiology, Type 2 Diabetes
16. November 2009 08:05
Aradigm Corporation today announced that the first patient was dosed in a 6-month, multicenter, international Phase 2 clinical trial of a novel version of inhaled ciprofloxacin (ARD-3150) in 40 adult patients with non-cystic fibrosis bronchiectasis.
[More]
13. November 2009 02:05
Today, PARI Respiratory Equipment launched a newly updated continuing education class, Managing Respiratory Patients Through Efficient Aerosol Delivery, rounding out their free learning program with seven classes for respiratory therapists, nurses, case managers, and pharmacists.
[More]
11. November 2009 06:19
Vertex Pharmaceuticals Incorporated announced today that holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $109.0 million in aggregate principal amount of those notes and accrued interest for approximately 4.8 million shares of the Company’s common stock, which is approximately 140,000 shares more than the number of shares into which the notes were convertible under their original terms.
[More]
5. November 2009 07:51
Inspire Pharmaceuticals, Inc. announced today financial results for the third quarter ended September 30, 2009, reporting a net loss of $8.5 million or ($0.12) per common share.
[More]
ff0c7387-a177-416c-977e-4d9cc2329121|0|.0
Posted in: Business / Finance
Tags: Antibiotic, Azithromycin, Conjunctivitis, Cyclosporine, Cystic Fibrosis, Dry Eye, Erythromycin, Fibrosis, Glaucoma, Hospital, Prophylaxis
5. November 2009 07:38
Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced financial results for the third quarter and nine months ended September 30, 2009 and recent highlights.
[More]
5. November 2009 03:15
With the current outbreak of influenza-like illnesses, many people are trying to boost their immune systems with supplements. Ginseng is often a key ingredient, but its therapeutic use may extend far beyond that. Researchers are now investigating whether ginseng can help relieve health problems ranging from diabetes to depression to erectile dysfunction.
[More]
284ffa41-1009-48dc-8c7f-5afc04ccec62|0|.0
Posted in: Pharmaceutical News
Tags: Antioxidant, Biotechnology, Cardiovascular Disease, Cataract, Cystic Fibrosis, Dentistry, Depression, Diabetes, Erectile Dysfunction, Exercise, Fibrosis, Ginseng, Influenza, Metabolic Syndrome, Obesity, Pharmacology, Physiology, Stress
5. November 2009 02:11
Scientists in Belgium have successfully differentiated human embryonic stem cells (hESC) into major cell types of lung epithelial tissue using a convenient air-liquid interface.
[More]
5. November 2009 01:01
Inspire Pharmaceuticals, Inc. announced today patient enrollment is complete in three of its late-stage clinical trials.
[More]
2. November 2009 07:35
Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has been awarded a grant for $2.2 million from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), aimed at advancing the development of novel influenza therapeutics for the treatment of seasonal and pandemic influenza.
[More]
3b89e21f-37ee-41f6-a12b-dcaa5e2ec2a3|0|.0
Posted in: Drug Trial News | Disease/Infection News
Tags: Allergy, Asthma, Biotechnology, Cystic Fibrosis, Fibrosis, H1N1, Influenza, Pandemic, Pathology, Pneumonia, Prophylaxis, Toxicology, Ventilator, Virus
2. November 2009 07:34
Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has secured $30.2 million in Series B financing. ARCH Venture Partners and Novartis Bioventures Fund co-led the round with participation from existing investors Polaris Venture Partners and 5AM Ventures.
[More]
2. November 2009 03:23
More than 80 percent of hepatitis C patients in each arm of the Phase 2 Study C208 achieved a sustained viral response (SVR) with a telaprevir-based regimen according to results of an intent-to-treat (ITT) analysis announced today by Vertex Pharmaceuticals Incorporated.
[More]
11534e5d-c858-43a7-ac02-f856bf8d8cd8|0|.0
Posted in: Drug Trial News
Tags: Abdominal Pain, Anemia, Biotechnology, Cancer, CDC, Cirrhosis, Cystic Fibrosis, Fibrosis, Headache, Hepatitis C, Hepatology, Hospital, Jaundice, Nausea, Ribavirin, Telaprevir, Virus
1. November 2009 23:49
Researchers from the University of Copenhagen and the Technical University of Denmark along with other collaborators in Denmark and the US found that the bacterium Pseudomonas aeruginosa can 'switch on' production of molecules that kill white blood cells - preventing the bacteria being eliminated by the body's immune system.
[More]
30. October 2009 05:43
University of Iowa President Sally Mason announced today a $26.4 million gift commitment from longtime UI benefactors John and Mary Pappajohn of Des Moines -- the largest single gift commitment ever for the UI from individual Iowa donors -- and said it will provide the university's new interdisciplinary Institute for Biomedical Discovery with "the catalyst it needs to reach its full potential."
[More]